Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(8):1029–1034. doi: 10.1038/bjc.1997.503

Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain.

H J Broxterman 1, G J Schuurhuis 1, J Lankelma 1, J W Oberink 1, C A Eekman 1, A M Claessen 1, K Hoekman 1, M Poot 1, H M Pinedo 1
PMCID: PMC2228098  PMID: 9376262

Abstract

Progress in our understanding of the contribution of P-glycoprotein (P-gp)-mediated resistance to chemotherapy failure in haematological as well as solid tumours has been hampered by the lack of highly sensitive, reliable methods for the detection of P-gp function in fresh human tumour cells. The present study identifies the novel nucleic acid stain SYTO16 as a highly sensitive and specific dye to assess P-gp function. The effect of P-gp is expressed here as the ratio of dye fluorescence (RF) from cells incubated with dye with or without 2 microM of the P-gp inhibitor PSC 833. Using flow cytometric analysis, an RF of 0.9 was found for SYTO16 in the KB3-1 (P-gp-) and 1.6 in KB8 (P-gp+) cells. Three types of patients' cells were studied: (1) in haematopoietic CD34+ cells, which are known to express P-gp, the RF was 6.0 for SYTO16 compared with 2.5 for rhodamine 123 and 1.3 for daunorubicin (mean of five individuals); (2) in acute myeloid leukaemia cells, the RF for SYTO16 was 1.0 in P-gp- and 4.5 in P-gp+ samples; (3) for the first time, we have quantitated P-gp function in fresh human solid tumour (sarcoma) cells. We found, in a P-gp+ leiomyosarcoma, an RF of 16 for SYTO16 and 2.7 for daunorubicin. This means that complete inhibition of P-gp function in these sarcoma cells would lead to an increase of daunorubicin accumulation with 170% compared with 30% in the CD34+ cells. Next, we showed that SYTO16 could be fixed in nuclei by 3.6% formaldehyde treatment, allowing quantification of the nuclear fluorescence on cytospins by laser scanning microscopy. In conclusion, SYTO16 proved to have a combination of favourable properties: it can be excited at 488 nm and has large fluorescence enhancement upon binding to nucleic acids, allowing the use of low, nontoxic (< 10 nM) concentrations. Because the RF for SYTO16 is much higher than for daunorubicin, it can be applied for the determination of P-gp function in relatively small numbers of low-P-gp-expressing tumour cells by laser scanning microscopy. Individual sarcomas were found to have high P-gp function compared with CD34+ cells. This assay may be used to select patients for P-gp modulation protocols.

Full text

PDF
1029

Images in this article

1032Figure 2
on p.1032
1032Figure 4
on p.1032

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck W. T., Grogan T. M., Willman C. L., Cordon-Cardo C., Parham D. M., Kuttesch J. F., Andreeff M., Bates S. E., Berard C. W., Boyett J. M. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996 Jul 1;56(13):3010–3020. [PubMed] [Google Scholar]
  2. Broxterman H. J., Feller N., Kuiper C. M., Boven E., Versantvoort C. H., Teerlink T., Pinedo H. M., Lankelma J. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts. Int J Cancer. 1995 Jun 9;61(6):880–886. doi: 10.1002/ijc.2910610622. [DOI] [PubMed] [Google Scholar]
  3. Broxterman H. J., Lankelma J., Pinedo H. M. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer. 1996 Jun;32A(6):1024–1033. doi: 10.1016/0959-8049(96)00045-7. [DOI] [PubMed] [Google Scholar]
  4. Broxterman H. J., Sonneveld P., Feller N., Ossenkoppele G. J., Währer D. C., Eekman C. A., Schoester M., Lankelma J., Pinedo H. M., Löwenberg B. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood. 1996 Jun 1;87(11):4809–4816. [PubMed] [Google Scholar]
  5. Chaudhary P. M., Roninson I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991 Jul 12;66(1):85–94. doi: 10.1016/0092-8674(91)90141-k. [DOI] [PubMed] [Google Scholar]
  6. Dairkee S. H., Deng G., Stampfer M. R., Waldman F. M., Smith H. S. Selective cell culture of primary breast carcinoma. Cancer Res. 1995 Jun 15;55(12):2516–2519. [PubMed] [Google Scholar]
  7. Feller N., Kuiper C. M., Lankelma J., Ruhdal J. K., Scheper R. J., Pinedo H. M., Broxterman H. J. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer. 1995 Sep;72(3):543–549. doi: 10.1038/bjc.1995.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ino T., Miyazaki H., Isogai M., Nomura T., Tsuzuki M., Tsuruo T., Ezaki K., Hirano M. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia. 1994 Sep;8(9):1492–1497. [PubMed] [Google Scholar]
  9. Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976 Nov 11;455(1):152–162. doi: 10.1016/0005-2736(76)90160-7. [DOI] [PubMed] [Google Scholar]
  10. Kartner N., Evernden-Porelle D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. 1985 Aug 29-Sep 4Nature. 316(6031):820–823. doi: 10.1038/316820a0. [DOI] [PubMed] [Google Scholar]
  11. Leith C. P., Chen I. M., Kopecky K. J., Appelbaum F. R., Head D. R., Godwin J. E., Weick J. K., Willman C. L. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood. 1995 Sep 15;86(6):2329–2342. [PubMed] [Google Scholar]
  12. Ljung B. M., Mayall B., Lottich C., Boyer C., Sylvester S. S., Leight G. S., Siegler H. F., Smith H. S. Cell dissociation techniques in human breast cancer--variations in tumor cell viability and DNA ploidy. Breast Cancer Res Treat. 1989 Mar;13(2):153–159. doi: 10.1007/BF01806527. [DOI] [PubMed] [Google Scholar]
  13. Marie J. P., Faussat-Suberville A. M., Zhou D., Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia. 1993 Jun;7(6):825–831. [PubMed] [Google Scholar]
  14. Neyfakh A. A., Serpinskaya A. S., Chervonsky A. V., Apasov S. G., Kazarov A. R. Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without drug selection. Exp Cell Res. 1989 Dec;185(2):496–505. doi: 10.1016/0014-4827(89)90318-2. [DOI] [PubMed] [Google Scholar]
  15. Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160–7164. doi: 10.1073/pnas.87.18.7160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ross D. D., Wooten P. J., Sridhara R., Ordóez J. V., Lee E. J., Schiffer C. A. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood. 1993 Aug 15;82(4):1288–1299. [PubMed] [Google Scholar]
  17. Scheper R. J., Bulte J. W., Brakkee J. G., Quak J. J., van der Schoot E., Balm A. J., Meijer C. J., Broxterman H. J., Kuiper C. M., Lankelma J. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer. 1988 Sep 15;42(3):389–394. doi: 10.1002/ijc.2910420314. [DOI] [PubMed] [Google Scholar]
  18. Spoelstra E. C., Westerhoff H. V., Dekker H., Lankelma J. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur J Biochem. 1992 Jul 15;207(2):567–579. doi: 10.1111/j.1432-1033.1992.tb17083.x. [DOI] [PubMed] [Google Scholar]
  19. Willingham M. C., Cornwell M. M., Cardarelli C. O., Gottesman M. M., Pastan I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res. 1986 Nov;46(11):5941–5946. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES